SELLAS Life Sciences Group, Inc. (SLS)
(Delayed Data from NSDQ)
$1.62 USD
+0.03 (1.89%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.63 +0.01 (0.62%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLS 1.62 +0.03(1.89%)
Will SLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Other News for SLS
Vanguard Group Inc's Strategic Acquisition in SELLAS Life Sciences Group Inc
Maxim Increases Price Target for Sellas Life Sciences (SLS) | SLS Stock News
Sellas Life Sciences price target raised by $3 at Maxim, here's why
SLS Stock: Maxim Group Raises Price Target by 75% to $7.00 | SLS Stock News
SELLAS Life Sciences (SLS) Rises on Promising AML Trial Results